vs
DOCUSIGN, INC.（DOCU）与百利高（PRGO）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是DOCUSIGN, INC.的1.4倍（$1.1B vs $818.4M），DOCUSIGN, INC.净利率更高（10.2% vs -127.8%，领先138.0%），DOCUSIGN, INC.同比增速更快（8.4% vs -2.5%），DOCUSIGN, INC.自由现金流更多（$262.9M vs $148.6M）
DocuSign是总部位于美国加利福尼亚州旧金山的软件企业，为各类机构提供多设备支持的电子协议管理及电子签名相关产品。截至2025年，公司在180个国家拥有约170万客户，其处理的签名符合美国ESIGN法案、欧盟eIDAS法规要求，满足欧盟高级及合格签名标准。
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
DOCU vs PRGO — 直观对比
营收规模更大
PRGO
是对方的1.4倍
$818.4M
营收增速更快
DOCU
高出10.9%
-2.5%
净利率更高
DOCU
高出138.0%
-127.8%
自由现金流更多
DOCU
多$114.3M
$148.6M
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $818.4M | $1.1B |
| 净利润 | $83.7M | $-1.4B |
| 毛利率 | 79.2% | 32.6% |
| 营业利润率 | 10.4% | -116.0% |
| 净利率 | 10.2% | -127.8% |
| 营收同比 | 8.4% | -2.5% |
| 净利润同比 | 34.1% | -3093.9% |
| 每股收益（稀释后） | $0.40 | $-10.23 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCUPRGO
| Q4 25 | $818.4M | $1.1B | ||
| Q3 25 | $800.6M | $1.0B | ||
| Q2 25 | $763.7M | $1.1B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
净利润DOCUPRGO
| Q4 25 | $83.7M | $-1.4B | ||
| Q3 25 | $63.0M | $7.5M | ||
| Q2 25 | $72.1M | $-8.4M | ||
| Q1 25 | — | $-6.4M | ||
| Q4 24 | — | $-44.4M | ||
| Q3 24 | — | $-21.0M | ||
| Q2 24 | — | $-108.4M | ||
| Q1 24 | — | $2.0M |
毛利率DOCUPRGO
| Q4 25 | 79.2% | 32.6% | ||
| Q3 25 | 79.3% | 36.1% | ||
| Q2 25 | 79.4% | 34.4% | ||
| Q1 25 | — | 37.6% | ||
| Q4 24 | — | 33.9% | ||
| Q3 24 | — | 37.2% | ||
| Q2 24 | — | 37.0% | ||
| Q1 24 | — | 33.1% |
营业利润率DOCUPRGO
| Q4 25 | 10.4% | -116.0% | ||
| Q3 25 | 8.1% | 7.0% | ||
| Q2 25 | 7.9% | 4.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | — | 7.4% | ||
| Q2 24 | — | -2.5% | ||
| Q1 24 | — | -5.1% |
净利率DOCUPRGO
| Q4 25 | 10.2% | -127.8% | ||
| Q3 25 | 7.9% | 0.7% | ||
| Q2 25 | 9.4% | -0.8% | ||
| Q1 25 | — | -0.6% | ||
| Q4 24 | — | -3.9% | ||
| Q3 24 | — | -1.9% | ||
| Q2 24 | — | -10.2% | ||
| Q1 24 | — | 0.2% |
每股收益（稀释后）DOCUPRGO
| Q4 25 | $0.40 | $-10.23 | ||
| Q3 25 | $0.30 | $0.05 | ||
| Q2 25 | $0.34 | $-0.06 | ||
| Q1 25 | — | $-0.05 | ||
| Q4 24 | — | $-0.32 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.79 | ||
| Q1 24 | — | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $583.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.0B | $2.9B |
| 总资产 | $4.0B | $8.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DOCUPRGO
| Q4 25 | $583.3M | — | ||
| Q3 25 | $600.0M | $432.1M | ||
| Q2 25 | $657.4M | $454.2M | ||
| Q1 25 | — | $409.9M | ||
| Q4 24 | — | $558.8M | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $542.8M | ||
| Q1 24 | — | $658.5M |
股东权益DOCUPRGO
| Q4 25 | $2.0B | $2.9B | ||
| Q3 25 | $2.0B | $4.4B | ||
| Q2 25 | $2.0B | $4.5B | ||
| Q1 25 | — | $4.4B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.6B | ||
| Q2 24 | — | $4.5B | ||
| Q1 24 | — | $4.7B |
总资产DOCUPRGO
| Q4 25 | $4.0B | $8.5B | ||
| Q3 25 | $3.9B | $10.1B | ||
| Q2 25 | $3.9B | $10.1B | ||
| Q1 25 | — | $9.8B | ||
| Q4 24 | — | $9.6B | ||
| Q3 24 | — | $11.2B | ||
| Q2 24 | — | $10.4B | ||
| Q1 24 | — | $10.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $290.3M | $175.4M |
| 自由现金流经营现金流 - 资本支出 | $262.9M | $148.6M |
| 自由现金流率自由现金流/营收 | 32.1% | 13.4% |
| 资本支出强度资本支出/营收 | 3.3% | 2.4% |
| 现金转化率经营现金流/净利润 | 3.47× | — |
| 过去12个月自由现金流最近4个季度 | — | $145.1M |
8季度趋势，按日历期对齐
经营现金流DOCUPRGO
| Q4 25 | $290.3M | $175.4M | ||
| Q3 25 | $246.1M | $51.7M | ||
| Q2 25 | $251.4M | $75.9M | ||
| Q1 25 | — | $-64.5M | ||
| Q4 24 | — | $312.6M | ||
| Q3 24 | — | $42.2M | ||
| Q2 24 | — | $9.5M | ||
| Q1 24 | — | $-1.4M |
自由现金流DOCUPRGO
| Q4 25 | $262.9M | $148.6M | ||
| Q3 25 | $217.6M | $29.8M | ||
| Q2 25 | $227.8M | $56.7M | ||
| Q1 25 | — | $-90.0M | ||
| Q4 24 | — | $274.9M | ||
| Q3 24 | — | $15.1M | ||
| Q2 24 | — | $-18.9M | ||
| Q1 24 | — | $-26.5M |
自由现金流率DOCUPRGO
| Q4 25 | 32.1% | 13.4% | ||
| Q3 25 | 27.2% | 2.9% | ||
| Q2 25 | 29.8% | 5.4% | ||
| Q1 25 | — | -8.6% | ||
| Q4 24 | — | 24.2% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | -1.8% | ||
| Q1 24 | — | -2.4% |
资本支出强度DOCUPRGO
| Q4 25 | 3.3% | 2.4% | ||
| Q3 25 | 3.6% | 2.1% | ||
| Q2 25 | 3.1% | 1.8% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 2.5% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 2.3% |
现金转化率DOCUPRGO
| Q4 25 | 3.47× | — | ||
| Q3 25 | 3.91× | 6.89× | ||
| Q2 25 | 3.49× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOCU
| Subscription And Circulation | $801.0M | 98% |
| Professional Services And Other | $17.4M | 2% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
